To the best of our knowledge, the extent to which EZH2 is a transcriptional repressor or activator, and the extent to which this may be associated with JAK3 mutational status, has not yet been explored in T-PLL, but has therapeutic implications. This evidence concerns the gene JAK3 and prolymphocytic leukemia.